{
  "id": "prostate",
  "title": "Prostate",
  "lang": "en",
  "source_lang": "en",
  "summary": "The prostate is an androgen-dependent reproductive gland surrounding the proximal urethra, important in semen production and affected by several common age-related and inflammatory disorders.",
  "category": "health",
  "subcategory": "anatomy-physiology",
  "type": "concept",
  "aliases": [
    "Prostate gland"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/prostate/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/prostate/",
      "json": "https://aiwiki.page/zh/prostate.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "The prostate is a fibromuscular, glandular organ of the reproductive system, situated below the urinary bladder and around the first part of the urethra. Its secretions contribute to semen and help regulate the physical and biochemical environment in which sperm are transported. The adult human prostate is approximately walnut-sized, although its dimensions vary considerably with age and disease. Its position at the junction of the urinary and reproductive tracts explains why prostatic disorders can affect urination, ejaculation, fertility, and sexual function.\n\nThe prostate is clinically important because benign prostatic hyperplasia, inflammatory syndromes, and prostate cancer are common but biologically distinct conditions. Enlargement does not necessarily indicate cancer, urinary symptoms do not identify a single underlying disorder, and early cancer often causes no symptoms. Understanding the gland therefore requires distinguishing its normal anatomy and secretory functions from changes in tissue growth, inflammation, and malignant transformation. Its dependence on androgens also makes it a major subject of research in developmental biology, endocrinology, and cancer treatment."
    },
    {
      "heading": "Gross anatomy and anatomical relationships",
      "text": "The human prostate lies in the lesser pelvis, immediately inferior to the bladder and anterior to the rectum. Its broad superior surface, or base, is continuous with the bladder neck; its narrower inferior apex approaches the external urethral sphincter and the perineal membrane. In a young adult, the gland commonly weighs about 20 grams and measures approximately 4 centimetres across, 3 centimetres vertically, and 2 centimetres from front to back. These are approximate anatomical dimensions rather than diagnostic limits: growth, individual variation, and measurement methods produce substantial differences.\n\nThe urethra passes through the gland from the bladder neck toward the apex. Along the posterior wall of this prostatic segment is the seminal colliculus, a raised landmark near the openings of the ejaculatory ducts. Each duct is formed by the union of a seminal-vesicle duct with the terminal part of a ductus deferens and travels through the prostate before opening into the urethra. Numerous smaller prostatic ducts discharge glandular secretions into the same urethral segment. This arrangement permits semen to enter a passage that also carries urine, although coordinated muscular activity normally separates the two functions.\n\nPosteriorly, a connective-tissue plane commonly called Denonvilliers’ fascia separates the prostate and seminal vesicles from the rectum. The short distance between the posterior prostate and the anterior rectal wall makes part of the gland accessible to rectal examination. Anteriorly, the prostate is separated from the pubic symphysis by a retropubic space containing connective tissue and venous structures. The outer fibromuscular boundary is often described as a capsule, but it is not a uniformly discrete anatomical shell. Its continuity with neighbouring structures matters when interpreting tumour extension and planning operations.\n\nArterial supply usually comes from branches of the internal iliac arterial system, particularly inferior vesical, internal pudendal, and middle rectal branches, with considerable variation. A dense venous plexus surrounds the gland and communicates with pelvic veins. Lymphatic drainage reaches pelvic nodes, including obturator and internal iliac groups, with additional routes to other pelvic stations. Autonomic nerves from the inferior hypogastric plexus regulate smooth muscle and secretion. Nerves important for penile erection run close to the posterolateral surface, often described clinically as neurovascular bundles. Their intimate relationship with the gland helps explain why prostate operations can affect erectile function even though erection itself does not originate in the prostate."
    },
    {
      "heading": "Zonal organization and microscopic structure",
      "text": "The prostate is not a uniform collection of glands. Its modern anatomical description distinguishes the peripheral, central, and transition zones, together with an anterior fibromuscular stroma. This zonal system, developed through the work of pathologist John McNeal, is more useful for many clinical purposes than the older division into right, left, median, and other lobes. The zones differ in their duct arrangements, tissue characteristics, and susceptibility to disease. Their relative proportions also change as the gland ages.\n\nIn a young adult, the peripheral zone accounts for roughly 70% of glandular tissue and occupies much of the posterior and lateral prostate. The central zone, approximately 20–25%, surrounds the ejaculatory ducts near the base. The transition zone initially constitutes only about 5–10% and surrounds the proximal prostatic urethra. Small periurethral glands lie close to the urethral wall. These percentages are approximate and become less representative when transition-zone enlargement compresses other regions. Most conventional prostate adenocarcinomas arise in the peripheral zone, whereas benign nodular hyperplasia develops chiefly in the transition zone and periurethral region.\n\nUnder the microscope, branching glands and ducts lie within stroma containing smooth muscle, fibroblasts, extracellular matrix, blood vessels, nerves, and immune cells. The glandular lining normally includes an inner layer of secretory luminal cells and an outer, sometimes discontinuous, basal-cell layer. Luminal cells produce many of the characteristic components of prostatic fluid and commonly express androgen receptors. Basal cells have a different molecular profile and contribute to epithelial maintenance. Scattered neuroendocrine cells release signalling molecules; these should not be confused with the uncommon, aggressive neuroendocrine cancers that can involve the prostate.\n\nThe appearance of this tissue is central to histopathological diagnosis. Conventional invasive adenocarcinoma typically forms abnormal glands lacking a basal-cell layer, but diagnosis depends on the overall combination of architecture, cellular features, and sometimes immunohistochemical staining rather than on one isolated finding. Benign glands may contain corpora amylacea, rounded laminated bodies that become more frequent with age and may calcify. These are not, by themselves, evidence of cancer. Stromal smooth muscle also has functional importance: its contraction helps expel secretion, while increased muscle tone can contribute to resistance at the bladder outlet independently of gland size."
    },
    {
      "heading": "Development, hormones, and changes across the lifespan",
      "text": "The prostate develops from epithelial buds arising from the embryonic urogenital sinus into surrounding mesenchymal tissue. In human development, this process begins during the first trimester, at approximately 10 weeks of gestation, and continues through branching and differentiation. Interactions between epithelium and mesenchyme determine the formation of ducts, secretory glands, and smooth-muscle-rich stroma. Prostatic development is therefore not simply the growth of a pre-existing miniature gland: it is an organized process of tissue induction governed by hormones and local signalling pathways.\n\nAndrogens are essential to this process. Testicular testosterone is converted within target tissues to dihydrotestosterone, or DHT, by 5-alpha-reductase enzymes. DHT binds the androgen receptor and changes the expression of genes involved in differentiation, growth, and secretion. The importance of this pathway is illustrated by inherited deficiency of 5-alpha-reductase type 2, in which the prostate is typically small or poorly developed. Androgen-receptor function is also necessary for the usual pattern of androgen-dependent reproductive development. These mechanisms distinguish the direct effects of circulating hormone concentrations from the additional effects of local metabolism and receptor activity.\n\nAfter relatively limited childhood growth, the prostate enlarges and acquires full secretory activity at puberty. Androgen signalling continues to support epithelial survival and function in adulthood. Experimental androgen withdrawal and its clinical use in prostate cancer demonstrate that substantial portions of prostatic tissue are hormone-responsive. The response is not uniform, however: epithelial and stromal compartments differ, and cancer cells can acquire mechanisms that sustain androgen-receptor signalling despite very low circulating testosterone.\n\nLater-life growth follows a different pattern from pubertal development. Benign hyperplastic nodules become increasingly common with age, especially around the urethra, but this is not adequately explained as a simple excess of testosterone. Local DHT production, stromal–epithelial interactions, growth factors, inflammatory processes, and age-related tissue changes all contribute. Circulating testosterone commonly declines with age even while benign enlargement becomes more frequent. Hormonal exposure also affects the gland in people receiving androgen suppression for other reasons; prostate tissue generally persists unless surgically removed. Lifelong anatomical presence, current hormone concentrations, gland size, and disease risk are thus related but not interchangeable characteristics."
    },
    {
      "heading": "Prostatic secretion and reproductive function",
      "text": "The prostate is an exocrine gland: its products are released through ducts into the urethra rather than principally into the bloodstream. Prostatic fluid usually contributes approximately one-fifth to one-third of ejaculate volume, while the seminal vesicles provide most of the remainder. Sperm are produced in the testes and mature in the epididymides; they are neither manufactured nor stored in the prostate. The gland instead adds a specialized fluid containing proteolytic enzymes, citrate, zinc, ions, and other substances that influence the properties of semen.\n\nOne of its best-known products is prostate-specific antigen, or PSA, also called kallikrein-related peptidase 3. PSA is a serine protease whose physiological function is associated with the breakdown of semenogelin proteins originating largely from the seminal vesicles. Immediately after ejaculation, semen commonly forms a loose coagulum. Proteolysis subsequently liquefies this material, helping release sperm from the gel-like matrix. PSA is therefore normally abundant in seminal fluid, whereas only small amounts enter the circulation. Its use as a blood marker derives from this tissue production, not from a unique association with malignancy.\n\nNormal secretory prostate cells accumulate unusually high concentrations of zinc and citrate compared with many other tissues. Zinc influences mitochondrial enzyme activity, including inhibition of aconitase, helping explain why these cells accumulate and secrete citrate rather than oxidizing all of it through the citric acid cycle. This specialized metabolism changes in many prostate cancers, which often contain lower citrate concentrations than normal glandular tissue. Prostatic secretion is generally slightly acidic, whereas the final pH of semen reflects contributions from several organs and is usually mildly alkaline. Describing the prostate alone as responsible for “neutralizing vaginal acidity” therefore oversimplifies the chemistry.\n\nDuring emission, sympathetic activity contracts the smooth muscle of the prostate and other reproductive structures, moving secretions into the posterior urethra. Closure of the bladder neck limits backward flow into the bladder, and coordinated contractions subsequently propel semen outward. These processes are related to, but distinct from, orgasm and erection. Removal of the prostate and seminal vesicles eliminates the usual seminal ejaculate, although orgasm may still occur. Operations that alter the bladder outlet can instead cause retrograde ejaculation, in which semen passes into the bladder. Such effects illustrate how secretion, sperm transport, outlet closure, and sensory experience depend on different anatomical and neural components."
    },
    {
      "heading": "Benign enlargement and lower urinary tract dysfunction",
      "text": "Benign prostatic hyperplasia, or BPH, is a histological process involving an increased number of stromal and epithelial cells, usually in the transition zone and periurethral tissues. It is not simply enlargement of individual cells, and it is not a premalignant lesion. Microscopic BPH becomes increasingly common with age: classic autopsy series found it in approximately half of men in their sixth decade and in a large majority at very advanced ages. These figures describe tissue findings, not the proportion experiencing troublesome symptoms or requiring treatment.\n\nSeveral terms distinguish related but different observations. BPH denotes the tissue process; benign prostatic enlargement denotes increased gland volume; and benign prostatic obstruction denotes impaired urinary outflow attributable to the prostate. Lower urinary tract symptoms include storage symptoms, such as frequency, urgency, and nocturia, and voiding symptoms, such as hesitancy, weak stream, intermittency, and straining. Post-void dribbling and a sensation of incomplete emptying may also occur. These categories overlap, but none establishes the cause. Similar complaints can result from bladder dysfunction, urethral narrowing, neurological disease, infection, or increased nighttime urine production.\n\nObstruction has both anatomical and functional components. Enlarging nodules can compress or distort the urethral channel, while smooth-muscle tone in the prostate and bladder neck increases outlet resistance. The configuration of growth matters: tissue protruding into the bladder can interfere with opening even when total prostate volume is not exceptionally large. Consequently, gland size correlates imperfectly with symptoms and obstruction. The bladder initially compensates by generating greater pressure, but sustained loading may be associated with muscle thickening, altered sensation, involuntary contractions, or reduced contractile effectiveness.\n\nComplications can include acute urinary retention, recurrent urinary tract infection, bladder stones, and bleeding. Severe, prolonged outlet obstruction may produce upper urinary tract dilatation and impair kidney function, although this is not the usual outcome of uncomplicated enlargement. An episode of retention may also be precipitated by medicines, anaesthesia, constipation, or acute illness rather than by abrupt gland growth. Because bladder and outlet abnormalities can coexist, relief of anatomical obstruction does not invariably resolve every symptom. This distinction is important in interpreting both clinical trials and individual treatment outcomes: improvement in urinary flow, reduction in symptom scores, and prevention of retention measure different aspects of disease."
    },
    {
      "heading": "Prostatitis and chronic pelvic pain syndromes",
      "text": "“Prostatitis” covers several conditions that are not all bacterial infections and do not all show demonstrable inflammation of the prostate. A widely used National Institutes of Health classification separates acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome, and asymptomatic inflammatory prostatitis. This classification replaced an older tendency to apply the same label to diverse combinations of pelvic pain, urinary disturbance, and inflammatory findings. It remains useful because the mechanisms, laboratory findings, and treatment evidence differ across the categories.\n\nAcute bacterial prostatitis is an infection that may cause fever, chills, dysuria, pelvic or perineal pain, and difficulty emptying the bladder. Enteric Gram-negative organisms, especially Escherichia coli, are common causes. Infection may arise through ascending urinary pathways or after urinary instrumentation. The prostate can be swollen and tender, and severe cases may involve bloodstream infection or sepsis. A prostatic abscess is an uncommon but important complication, particularly in susceptible patients. Clinical assessment relies on the pattern of illness and microbiological evidence; vigorous prostatic massage is avoided in suspected acute bacterial infection because of pain and the risk of spreading infection.\n\nChronic bacterial prostatitis is characterized by persistent or recurrent bacterial infection involving the prostate, sometimes presenting as repeated urinary infections with the same organism. Bacteria may persist in prostatic ducts, and successful drug delivery depends partly on penetration into prostatic tissue. This condition differs from chronic prostatitis/chronic pelvic pain syndrome, in which persistent pelvic-region pain occurs without an established bacterial cause on standard testing. Pain may involve the perineum, penis, testes, suprapubic region, or ejaculation. Urinary and sexual symptoms can coexist, but neither their presence nor their severity proves an ongoing infection.\n\nChronic pelvic pain syndrome is understood as heterogeneous. Proposed contributing mechanisms include pelvic-floor muscle dysfunction, local immune activity, altered peripheral nerve signalling, and changes in central pain processing. Inflammatory cells may or may not be found in prostatic secretions or semen, and these findings do not consistently correspond to symptom severity. Chronic pain can also interact with sleep, mood, and daily functioning without being explained by a purely psychological origin. Asymptomatic inflammatory prostatitis, by contrast, is discovered incidentally during investigation for another reason. Across these categories, the word “prostatitis” therefore requires qualification: it may refer to proven infection, a chronic pain syndrome, or an incidental tissue finding rather than to one disease with a single cause."
    },
    {
      "heading": "Malignant disease and patterns of spread",
      "text": "Prostate cancer is usually an adenocarcinoma derived from glandular epithelial cells. Its biological behaviour ranges from small, slowly growing lesions that may never become clinically important to aggressive tumours capable of early dissemination. Many cancers arise in the peripheral zone, away from the urethral channel. This helps explain why localized disease often produces no urinary symptoms, while benign transition-zone enlargement may cause substantial obstruction. Conversely, advanced cancer can obstruct the urinary tract, and benign enlargement and malignancy may occur in the same gland.\n\nAge, family history, and inherited susceptibility are established determinants of risk. Pathogenic variants in genes such as BRCA2 and certain DNA repair genes can increase susceptibility and influence clinical behaviour. Incidence also varies between populations because of differences in age structure, ancestry-associated risk, testing practices, and access to diagnosis. PSA testing greatly affects recorded incidence by identifying cancers that would otherwise remain undetected. Comparisons of population rates therefore require separating underlying disease occurrence from the intensity of investigation.\n\nMicroscopic grading assesses tumour architecture rather than simply the size of abnormal cells. The Gleason system assigns patterns reflecting the degree of gland formation, and contemporary reporting commonly combines the score with Grade Groups 1–5. A score of 3 + 4 and a score of 4 + 3 both total 7, but the latter contains a greater proportion of the more adverse pattern and is classified differently. Staging addresses a separate question: whether disease remains confined to the prostate, extends beyond it, involves regional lymph nodes, or has spread to distant sites. Grade and stage contribute complementary information about prognosis.\n\nLocal extension can involve tissues around the prostate, the seminal vesicles, or the bladder neck. Spread through lymphatic routes reaches pelvic nodes, while distant metastases commonly involve bone, especially the axial skeleton. Skeletal lesions are often osteoblastic on imaging, although mixed destructive and bone-forming processes occur. Advanced disease may cause pain, anaemia, fractures, or spinal cord compression. At the molecular level, androgen-receptor signalling is a major driver in many tumours, but progression can involve altered receptor activity, DNA repair defects, changes in cellular metabolism, and lineage plasticity. This diversity explains why a tissue diagnosis of “prostate cancer” does not by itself specify its likely pace or response to treatment."
    },
    {
      "heading": "Clinical examination, biomarkers, and imaging",
      "text": "Evaluation of the prostate begins with the clinical question rather than with a single universal test. A medical history can distinguish pain, infection-related symptoms, urinary obstruction, storage disturbance, blood in the urine, and concerns arising from cancer risk. A digital rectal examination assesses the accessible posterior surface for approximate size, symmetry, consistency, tenderness, or nodules. It cannot reliably measure the whole gland or exclude cancer: some lesions are too small, too anterior, or otherwise beyond palpation. Urine testing, kidney-function measurements, and assessment of residual urine address different possible consequences or alternative causes of symptoms.\n\nPSA is a prostate-associated biomarker, not a cancer-specific test. Its blood concentration can rise with benign enlargement, inflammation, urinary retention, and some procedures as well as with cancer. Conversely, some cancers occur at relatively low PSA concentrations. Interpretation may incorporate age, previous results, gland volume, medication exposure, examination findings, and family history. PSA density expresses the serum PSA concentration relative to prostate volume, but its meaning depends on the accuracy of both measurements. Drugs that inhibit 5-alpha-reductase commonly reduce PSA substantially, complicating comparisons with untreated populations.\n\nUltrasonography can estimate gland volume, evaluate residual urine, and guide procedures. Magnetic resonance imaging, particularly multiparametric MRI, depicts zonal anatomy and identifies lesions with combinations of T2-weighted appearances, diffusion characteristics, and sometimes contrast enhancement. The Prostate Imaging Reporting and Data System, or PI-RADS, standardizes assessment of the likelihood of clinically significant cancer. MRI can guide targeted biopsy, often alongside systematic sampling, but a negative scan does not exclude every significant tumour. Tissue samples establish histological diagnosis. Transperineal sampling avoids passing the needle through the rectal wall and generally has a lower infectious risk than transrectal sampling.\n\nTesting people without symptoms is screening, distinct from investigating symptoms or monitoring established disease. Randomized studies of PSA-based screening have shown that screening can reduce prostate-cancer mortality in some settings, while also increasing diagnosis of cancers that would not otherwise have caused harm. Overdiagnosis differs from a false-positive result: the cancer is genuinely present, but its detection does not improve the person’s lifespan or health. Screening policies therefore vary in age ranges, intervals, and risk assessment. Shared decision-making addresses the competing possibilities of earlier detection, additional imaging or biopsy, unnecessary diagnosis, and treatment-related harms rather than treating PSA as a simple positive-or-negative verdict."
    },
    {
      "heading": "Medical, surgical, and oncological treatment principles",
      "text": "Treatment differs fundamentally between benign outlet disease, infection, chronic pain syndromes, and malignancy. For symptoms attributed to benign enlargement, alpha-1 adrenergic antagonists reduce smooth-muscle tone in the prostate and bladder neck without removing tissue. Finasteride and dutasteride inhibit 5-alpha-reductase, reduce DHT production, and gradually decrease prostate volume in many patients with enlarged glands. Their effects develop more slowly and include reductions in the risk of retention and subsequent intervention in selected populations. Other medicines target associated bladder storage dysfunction, while tadalafil can improve lower urinary tract symptoms through mechanisms distinct from shrinking the gland.\n\nProcedures for benign obstruction aim to enlarge the urinary passage. Transurethral resection removes obstructing tissue through an instrument introduced into the urethra. Laser techniques may vaporize tissue or enucleate enlarged adenomatous tissue along anatomical planes. Other approaches include mechanical retraction, water-vapour ablation, waterjet tissue removal, and prostatic artery embolization. These interventions differ in tissue removal, durability, retreatment rates, bleeding, anaesthetic requirements, and effects on ejaculation. A simple prostatectomy for very large benign enlargement removes the obstructing inner adenoma; it is not equivalent to radical prostatectomy for cancer, which removes the whole gland and usually the seminal vesicles.\n\nBacterial prostatitis is treated with antibiotics selected according to the likely organism, culture findings, drug penetration, and severity of infection. Chronic pelvic pain syndromes do not have an equivalent single pathogen-directed treatment. Studied approaches include medicines directed at particular symptom domains, pelvic-floor interventions, and broader pain-management strategies, with variable evidence across subgroups. Repeated antibiotic exposure in the absence of demonstrated infection has to be distinguished from treatment of confirmed bacterial disease, particularly because of adverse effects and antimicrobial resistance.\n\nFor localized prostate cancer, management may include active surveillance, radical prostatectomy, or radiation therapy. Active surveillance uses scheduled clinical assessment, PSA testing, imaging, and repeat tissue sampling to detect evidence that a selected low-risk cancer is becoming more consequential; it is not the absence of follow-up. More advanced disease may involve androgen-deprivation therapy, androgen-receptor pathway inhibitors, chemotherapy, molecularly targeted drugs, or radiopharmaceuticals in defined settings. Outcomes must include more than tumour control. Radical treatment can affect continence, ejaculation, and erectile function, while systemic hormonal treatment can influence bone density, body composition, metabolic health, and sexual function. Anatomical preservation and nerve-sparing techniques can reduce some functional harms but do not eliminate them."
    },
    {
      "heading": "Historical study and contemporary research",
      "text": "Descriptions of structures corresponding to the prostate appear in ancient anatomical writing, although historical terminology did not always map cleanly onto the modern organ. The name derives from Greek language associated with standing before or in front. Renaissance dissection and later microscopic investigation gradually clarified its relationship to the bladder, urethra, and reproductive ducts. For centuries, however, the gland was understood as much through its consequences—particularly urinary retention in older men—as through a clear account of its secretory biology. Reliable distinctions between benign enlargement, infection, and malignancy developed with pathological examination and improved clinical investigation.\n\nSurgical treatment advanced substantially in the late nineteenth and early twentieth centuries, as anaesthesia, antisepsis, and operative techniques made removal of obstructing tissue more practicable. Hugh Hampton Young performed an early radical perineal prostatectomy for cancer in 1904. Later development of transurethral instruments permitted treatment of benign obstruction without an open incision. Anatomical studies by Patrick Walsh and colleagues in the early 1980s clarified the relationship between the prostate and nerves involved in erection, supporting nerve-sparing radical prostatectomy. These changes linked increasingly detailed anatomy to attempts to preserve function as well as remove disease.\n\nA major endocrine discovery came in 1941, when Charles Huggins and Clarence Hodges reported that reducing androgen stimulation could produce responses in advanced prostate cancer, assessed in part through changes in serum acid phosphatase. This work established hormonal manipulation as a foundation of treatment; Huggins received the Nobel Prize in Physiology or Medicine in 1966 for discoveries concerning hormonal treatment of prostate cancer. PSA assays later transformed detection and follow-up. Their widespread clinical adoption in the late twentieth century also made overdiagnosis and the consequences of treating indolent disease central research questions.\n\nContemporary research integrates tissue anatomy with molecular profiling, imaging, and long-term clinical outcomes. Single-cell studies distinguish epithelial, stromal, and immune populations rather than treating the prostate as a single tissue compartment. Organoids and other experimental systems allow investigation of development, treatment resistance, and interactions between cell types, although they cannot reproduce every feature of the intact organ. Prostate-specific membrane antigen imaging and targeted radioligand treatment have expanded approaches to advanced cancer; this membrane protein is distinct from the secreted PSA measured in blood. Continuing studies examine how to identify clinically consequential disease more precisely, explain heterogeneous chronic pelvic pain, and separate the contributions of prostate growth and bladder dysfunction to urinary symptoms."
    }
  ],
  "links": [
    "organ",
    "benign-prostatic-hyperplasia",
    "prostate-cancer",
    "lymphatic-system",
    "histopathology",
    "metabolism",
    "urinary-tract-infection",
    "kidney",
    "sepsis",
    "chronic-pain",
    "incidence",
    "cancer-staging",
    "metastasis",
    "medical-history",
    "biomarker",
    "ultrasonography",
    "magnetic-resonance-imaging",
    "biopsy",
    "cancer-screening",
    "overdiagnosis",
    "shared-decision-making",
    "antibiotic",
    "antimicrobial-resistance",
    "radiation-therapy",
    "erectile-dysfunction",
    "nobel-prize-in-physiology-or-medicine"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}